Literature DB >> 28162137

Are Parkinson's Patients More Vulnerable to the Effects of Cardiovascular Risk: A Neuroimaging and Neuropsychological Study.

Jacob D Jones1, Jared J Tanner1, Michael Okun2, Catherine C Price1, Dawn Bowers1.   

Abstract

OBJECTIVES: This study examined whether individuals with Parkinson's disease (PD) are at increased vulnerability for vascular-related cognitive impairment relative to controls. The underlying assumption behind this hypothesis relates to brain reserve and that both PD and vascular risk factors impair similar fronto-executive cognitive systems.
METHODS: The sample included 67 PD patients and 61 older controls (total N=128). Participants completed neuropsychological measures of executive functioning, processing speed, verbal delayed recall/memory, language, and auditory attention. Cardiovascular risk was assessed with the Framingham Cardiovascular Risk index. Participants underwent brain imaging (T1 and T2 FLAIR). Trained raters measured total and regional leukoaraiosis (periventricular, deep subcortical, and infracortical).
RESULTS: Hierarchical regressions revealed that more severe cardiovascular risk was related to worse executive functioning, processing speed, and delayed verbal recall in both Parkinson patients and controls. More severe cardiovascular risk was related to worse language functioning in the PD group, but not controls. In contrast, leukoaraiosis related to both cardiovascular risk and executive functioning for controls, but not the PD group.
CONCLUSIONS: Overall, results revealed that PD and cardiovascular risk factors are independent risk factors for cognitive impairment. Generally, the influence of cardiovascular risk factors on cognition is similar in PD patients and controls. (JINS, 2017, 23, 322-331).

Entities:  

Keywords:  Cerebrovascular diseases; Cognition; Executive function; Magnetic resonance imaging; Memory; Parkinson’s disease

Mesh:

Year:  2017        PMID: 28162137      PMCID: PMC5729910          DOI: 10.1017/S1355617717000017

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  40 in total

1.  The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease.

Authors:  K Haugarvoll; D Aarsland; T Wentzel-Larsen; J P Larsen
Journal:  Acta Neurol Scand       Date:  2005-12       Impact factor: 3.209

2.  Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways.

Authors:  R Hilker; A V Thomas; J C Klein; S Weisenbach; E Kalbe; L Burghaus; A H Jacobs; K Herholz; W D Heiss
Journal:  Neurology       Date:  2005-12-13       Impact factor: 9.910

3.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

Review 4.  From Binswanger's disease to leuokoaraiosis: what we have learned about subcortical vascular dementia.

Authors:  David J Libon; Catherine C Price; Kelly Davis Garrett; Tania Giovannetti
Journal:  Clin Neuropsychol       Date:  2004-02       Impact factor: 3.535

5.  ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension.

Authors:  Wilbert S Aronow; Jerome L Fleg; Carl J Pepine; Nancy T Artinian; George Bakris; Alan S Brown; Keith C Ferdinand; Mary Ann Forciea; William H Frishman; Cheryl Jaigobin; John B Kostis; Giuseppi Mancia; Suzanne Oparil; Eduardo Ortiz; Efrain Reisin; Michael W Rich; Douglas D Schocken; Michael A Weber; Deborah J Wesley
Journal:  J Am Coll Cardiol       Date:  2011-04-26       Impact factor: 24.094

6.  White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease.

Authors:  Turi O Dalaker; Jan P Larsen; Michael G Dwyer; Dag Aarsland; Mona K Beyer; Guido Alves; Kolbjorn Bronnick; Ole-Bjorn Tysnes; Robert Zivadinov
Journal:  Neuroimage       Date:  2009-06-16       Impact factor: 6.556

7.  Effect of olfactory impairment and white matter hyperintensities on cognition in Parkinson's disease.

Authors:  Jee Hyun Ham; Jae Jung Lee; Mun-Kyung Sunwoo; Jin Yong Hong; Young H Sohn; Phil Hyu Lee
Journal:  Parkinsonism Relat Disord       Date:  2015-12-31       Impact factor: 4.891

8.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

9.  Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease.

Authors:  Giulio Scigliano; Gabriele Ronchetti; Floriano Girotti; Massimo Musicco
Journal:  Parkinsonism Relat Disord       Date:  2008-06-16       Impact factor: 4.891

Review 10.  Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis.

Authors:  Angie A Kehagia; Roger A Barker; Trevor W Robbins
Journal:  Neurodegener Dis       Date:  2012-10-03       Impact factor: 2.977

View more
  9 in total

1.  Gastrointestinal symptoms are predictive of trajectories of cognitive functioning in de novo Parkinson's disease.

Authors:  Jacob D Jones; Elizabeth Rahmani; Erik Garcia; Jonathan P Jacobs
Journal:  Parkinsonism Relat Disord       Date:  2020-01-25       Impact factor: 4.891

2.  Neuroimaging cerebrovascular biomarkers in Parkinson's disease.

Authors:  Mariana Alves; Patrícia Pita Lobo; Linda Azevedo Kauppila; Leonor Rebordão; M Manuela Cruz; Carla Guerreiro; José M Ferro; Joaquim J Ferreira; Sofia Reimão
Journal:  Neuroradiol J       Date:  2021-12-06

3.  Statistically Defined Parkinson's Disease Executive and Memory Cognitive Phenotypes: Demographic, Behavioral, and Structural Neuroimaging Comparisons.

Authors:  Samuel J Crowley; Guita Banan; Manish Amin; Jared J Tanner; Loren Hizel; Peter Nguyen; Babette Brumback; Katie Rodriguez; Nikolaus McFarland; Dawn Bowers; Mingzhou Ding; Thomas A Mareci; Catherine C Price
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

4.  Structural brain correlates of fatigue in older adults with and without Parkinson's disease.

Authors:  Benzi M Kluger; Qing Zhao; Jared J Tanner; Nadine A Schwab; Shellie-Anne Levy; Sarah E Burke; Haiqing Huang; Mingzhou Ding; Catherine Price
Journal:  Neuroimage Clin       Date:  2019-02-21       Impact factor: 4.881

5.  Cognitive subtypes in individuals with essential tremor seeking deep brain stimulation.

Authors:  Adrianna M Ratajska; Francesca V Lopez; Lauren Kenney; Charles Jacobson; Kelly D Foote; Michael S Okun; Dawn Bowers
Journal:  Clin Neuropsychol       Date:  2021-02-10       Impact factor: 4.373

6.  White matter hyperintensities are linked to future cognitive decline in de novo Parkinson's disease patients.

Authors:  Mahsa Dadar; Yashar Zeighami; Yvonne Yau; Seyed-Mohammad Fereshtehnejad; Josefina Maranzano; Ronald B Postuma; Alain Dagher; D Louis Collins
Journal:  Neuroimage Clin       Date:  2018-09-27       Impact factor: 4.881

7.  Mapping Actuarial Criteria for Parkinson's Disease-Mild Cognitive Impairment onto Data-Driven Cognitive Phenotypes.

Authors:  Lauren E Kenney; Adrianna M Ratajska; Francesca V Lopez; Catherine C Price; Melissa J Armstrong; Dawn Bowers
Journal:  Brain Sci       Date:  2021-12-30

Review 8.  The influence of white matter hyperintensity on cognitive impairment in Parkinson's disease.

Authors:  Hailing Liu; Bin Deng; Fen Xie; Xiaohua Yang; Zhenchao Xie; Yonghua Chen; Zhi Yang; Xiyan Huang; Shuzhen Zhu; Qing Wang
Journal:  Ann Clin Transl Neurol       Date:  2021-07-26       Impact factor: 4.511

9.  Characteristics of Parkinson's Disease in Patients with and without Cognitive Impairment.

Authors:  Julie M Chandler; Radhika Nair; Kevin Biglan; Erin A Ferries; Leanne M Munsie; Tich Changamire; Nick Patel
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.